Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1
Xian Li,Mengxin Xu,Jingyi Yang,Li Zhou,Lin Liu,Min Li,Shasha Wang,Mei-Qin Liu,Zhixiang Huang,Zhen Zhang,Shuning Liu,Yunqi Hu,Haofeng Lin,Bowen Liu,Ying Sun,Qingguo Wu,Zheng-Li Shi,Ke Lan,Yu Chen,Huimin Yan,Yao-Qing Chen
DOI: https://doi.org/10.1038/s41392-024-01822-3
IF: 39.3
2024-04-27
Signal Transduction and Targeted Therapy
Abstract:Developing a mucosal vaccine against SARS-CoV-2 is critical for combatting the epidemic. Here, we investigated long-term immune responses and protection against SARS-CoV-2 for the intranasal vaccination of a triple receptor-binding domain (RBD) scaffold protein (3R-NC) adjuvanted with a flagellin protein (KFD) ( 3R-NC + KFDi.n ). In mice, the vaccination elicited RBD-specific broad-neutralizing antibody responses in both serum and mucosal sites sustained at high level over a year. This long-lasting humoral immunity was correlated with the presence of long-lived RBD-specific IgG- and IgA-producing plasma cells, alongside the Th17 and Tfh17-biased T-cell responses driven by the KFD adjuvant. Based upon these preclinical findings, an open labeled clinical trial was conducted in individuals who had been primed with the inactivated SARS-CoV-2 (IAV) vaccine. With a favorable safety profile, the 3R-NC + KFDi.n boost elicited enduring broad-neutralizing IgG in plasma and IgA in salivary secretions. To meet the challenge of frequently emerged variants, we further designed an updated triple-RBD scaffold protein with mutated RBD combinations, which can induce adaptable antibody responses to neutralize the newly emerging variants, including JN.1. Our findings highlight the potential of the KFD-adjuvanted triple-RBD scaffold protein is a promising prototype for the development of a mucosal vaccine against SARS-CoV-2 infection.
biochemistry & molecular biology,cell biology